• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Trial.

作者信息

Provencher Steeve, Potus François, Blais-Lecours Pascale, Bernard Sarah, Martineau Sandra, Breuils-Bonnet Sandra, Weatherald Jason, Sweeney Mike, Kulikowski Ewelina, Boucherat Olivier, Bonnet Sebastien

机构信息

Université Laval Québec City, Québec, Canada.

University of Calgary Calgary, Alberta, Canada.

出版信息

Am J Respir Crit Care Med. 2022 Jun 1;205(11):1357-1360. doi: 10.1164/rccm.202109-2182LE.

DOI:10.1164/rccm.202109-2182LE
PMID:35289736
Abstract
摘要

相似文献

1
BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Trial.BET蛋白抑制用于肺动脉高压：一项试点临床试验。
Am J Respir Crit Care Med. 2022 Jun 1;205(11):1357-1360. doi: 10.1164/rccm.202109-2182LE.
2
Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension.多中心临床前验证 BET 抑制剂治疗肺动脉高压。
Am J Respir Crit Care Med. 2019 Oct 1;200(7):910-920. doi: 10.1164/rccm.201812-2275OC.
3
EpiHope for the Treatment of Pulmonary Arterial Hypertension: Selective versus Nonselective BET Inhibition.EpiHope用于治疗肺动脉高压：选择性与非选择性BET抑制作用
Am J Respir Crit Care Med. 2019 Nov 1;200(9):1188-1190. doi: 10.1164/rccm.201906-1235LE.
4
BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?溴结构域和额外末端结构域（BET）信号传导：肺动脉高压的新型治疗靶点？
Am J Respir Crit Care Med. 2020 May 15;201(10):1313. doi: 10.1164/rccm.201912-2525LE.
5
Reply to Chen : BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?对陈的回复：BET信号传导：肺动脉高压的新型治疗靶点？
Am J Respir Crit Care Med. 2020 May 15;201(10):1313-1314. doi: 10.1164/rccm.202001-0059LE.
6
BET Bromodomain Inhibitors and Pulmonary Arterial Hypertension: Take Care of the Heart.BET溴结构域抑制剂与肺动脉高压：关注心脏
Am J Respir Crit Care Med. 2019 Nov 1;200(9):1187-1188. doi: 10.1164/rccm.201905-0993LE.
7
Inhibition of Siah2 ubiquitin ligase ameliorates monocrotaline-induced pulmonary arterial remodeling through inactivation of YAP.抑制 Siah2 泛素连接酶通过失活 YAP 改善野百合碱诱导的肺动脉重构。
Life Sci. 2020 Feb 1;242:117159. doi: 10.1016/j.lfs.2019.117159. Epub 2019 Dec 11.
8
Clinical application of pulmonary vascular resistance in patients with pulmonary arterial hypertension.肺血管阻力在肺动脉高压患者中的临床应用
J Cardiothorac Surg. 2021 Oct 20;16(1):311. doi: 10.1186/s13019-021-01696-4.
9
Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials.风险算法在肺动脉高压临床试验中的富集效益。
Am J Respir Crit Care Med. 2021 Mar 15;203(6):726-736. doi: 10.1164/rccm.202002-0357OC.
10
Pulmonary Arterial Hypertension Secondary to Drugs and Toxins.药物和毒素导致的肺动脉高压。
Clin Chest Med. 2021 Mar;42(1):19-38. doi: 10.1016/j.ccm.2020.11.008.

引用本文的文献

1
Rewriting the vascular script: epigenetic modifiers as scribes of metabolic reprogramming in pulmonary hypertension.改写血管脚本：表观遗传修饰因子作为肺动脉高压中代谢重编程的书写者
J Mol Med (Berl). 2025 Sep 3. doi: 10.1007/s00109-025-02589-y.
2
Lung Single-Cell Transcriptomics Reveal Diverging Pathobiology and Opportunities for Precision Targeting in Scleroderma-Associated Versus Idiopathic Pulmonary Arterial Hypertension.肺部单细胞转录组学揭示了硬皮病相关与特发性肺动脉高压不同的病理生物学及精准靶向治疗机会。
Circ Genom Precis Med. 2025 Jul 21:e004936. doi: 10.1161/CIRCGEN.124.004936.
3
Therapeutic targets for pulmonary arterial hypertension: insights into the emerging landscape.
肺动脉高压的治疗靶点：对新出现格局的见解
Expert Opin Ther Targets. 2025 Jun;29(6):327-343. doi: 10.1080/14728222.2025.2507034. Epub 2025 May 21.
4
The Use of Apabetalone in Reducing Cardiovascular Outcomes, Based on the Current Evidence and Trials.基于当前证据和试验，阿伐贝酮在降低心血管疾病结局方面的应用
Eur Cardiol. 2025 Feb 28;20:e04. doi: 10.15420/ecr.2023.38. eCollection 2025.
5
New therapies in pulmonary arterial hypertension: Recent insights.肺动脉高压的新疗法：近期见解
Int J Cardiol Congenit Heart Dis. 2025 Jan 30;19:100571. doi: 10.1016/j.ijcchd.2025.100571. eCollection 2025 Mar.
6
Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series).肺血管疾病的精准医学：未来已来（2023年格罗弗会议系列）
Pulm Circ. 2025 Jan 2;15(1):e70027. doi: 10.1002/pul2.70027. eCollection 2025 Jan.
7
Epigenetics-targeted drugs: current paradigms and future challenges.表观遗传学靶向药物：当前范例与未来挑战。
Signal Transduct Target Ther. 2024 Nov 26;9(1):332. doi: 10.1038/s41392-024-02039-0.
8
Epigenetic mechanisms mediate cytochrome P450 1A1 expression and lung endothelial injury caused by MRSA in vitro and in vivo.表观遗传机制介导耐甲氧西林金黄色葡萄球菌在体外和体内引起的细胞色素 P4501A1 表达和肺血管内皮损伤。
FASEB J. 2024 Nov 30;38(22):e70205. doi: 10.1096/fj.202401812R.
9
Targeting lysine acetylation readers and writers.靶向赖氨酸乙酰化的识别蛋白和写入蛋白。
Nat Rev Drug Discov. 2025 Feb;24(2):112-133. doi: 10.1038/s41573-024-01080-6. Epub 2024 Nov 21.
10
Single-cell transcriptomics reveal diverging pathobiology and opportunities for precision targeting in scleroderma-associated versus idiopathic pulmonary arterial hypertension.单细胞转录组学揭示了硬皮病相关性与特发性肺动脉高压不同的病理生物学及精准靶向治疗机会。
bioRxiv. 2024 Oct 25:2024.10.25.620225. doi: 10.1101/2024.10.25.620225.